Buntanetape updates

[Farooqji]

a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024.

finance.yahoo.com/news/anno...

[PDTom]

"Buntanetap" is my favourite, the results will be available in early 2024! I have also secured 3,000 shares. 🙂

[kaypeeoh in reply to PDTom]

"Buntanetap was safe and well tolerated. Biomarker data indicated a trend in lowering levels of neurotoxic proteins and inflammatory factors and improving axonal integrity and synaptic function in both AD and PD cohorts. .." This interests me as I was diagnosed with MS before being diagnosed with PD. How did you secure shares?

[PDTom in reply to kaypeeoh]

The shares secured? They are freely available for purchase. I bought 3,000 shares at 7.70 euros. They should go up to 1,000 euros if buntanetap is successful! I am optimistic! 😀

[redhawk1 in reply to PDTom]

Price of a share of stock has made a very strong move up this week!! Hope there is a good basis for this! Hope PDTom will make a boat load of money!!!

[Btraveria1 in reply to PDTom]

I too bought shares and am watching them rise😄

[redhawk1 in reply to PDTom]

By the way, PDTom, were you in the trial? If so, did you experience positive results?

[kaypeeoh]

Still interested but I'm sure wife wouldn't go into our retirement funds. Nevertheless, it's good to see any movement on AD treatment.

[emstadler71]

I bought shares too two weeks ago (only 50) at around $6 - Today is almost $11

[gomelgo]

Anyone willing to share instructions for stock dummies like myself? Where do I go to check out the stock and do I need a broker?

[Rupa88]

wow

Instead of being curious about the effects of this medication all you talk is about the stocks...

Hopefully it means that you are doing very well with Parkibson and do not have any problems

[Ghmac]

it has been discussed before now, along with the study results.

[Farooqji]

I have received following email from ANNOVIS BIO

Dear Friends,

We are making steady progress towards the readout of the Parkinson’s phase 3 and the Alzheimer phase 2/3 study. Stay tuned.

Since we grew from 2 to 12 employees, I want to inform you that we have moved; here is our new address:

Annovis Bio

101 Lindenwood Drive, Suite # 225

Malvern, PA 19355

annovisbio.com

484-875-3192

All the best and have a beautiful and blessed Holiday Season,

Maria

[Pegcity]

I got the same email. I hope it's not a PR stunt and am keeping my fingers crossed.